The Role of NK Cells and T Cells in the Rejection of Embryonic Stem Cell-Derived Tissues
Embryonic stem (ES) cells provide a unique opportunity for the establishment of new cell-based therapies that could benefit human health in the future. However, before that step can be taken, we need to better understand how to manipulate the differentiation of stem cells into cell lineages of interest and to define the immunological characteristics of these cells in the context of allogeneic transplantation. Here, we will discuss the interaction of ES cell progenitors with alloreactive T cells and NK cells and discuss how low MHC expression by ES cell derivatives may be exploited for therapies in humans.
KeywordsMajor Histocompatibility Complex Embryonic Stem Embryonic Stem Cell Human Leukocyte Antigen Major Histocompatibility Complex Class
This work would not have been possible without grants NIH/NHLBI 5R01HL073015-08 and the VA Merit Review Award 1I01BX001125-01
- 6.Kim EM, Zavazava N (2010) Low antigenicity of hematopoietic progenitor cells derived from human ES cells. Transplant Res Risk Manage 2:15–22Google Scholar
- 11.Baxter-Lowe LA, Maiers M, Spellman SR, Haagenson MD, Wang T, Fernandez-Vina M, Marsh SG, Horowitz M, Hurley CK (2009) HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States. Biol Blood Marrow Transplant 15:971–981PubMedCrossRefGoogle Scholar
- 14.Koch KS, Son KH, Maehr R, Pellicciotta I, Ploegh HL, Zanetti M, Sell S, Leffert HL (2006) Immune-privileged embryonic Swiss mouse STO and STO cell-derived progenitor cells: major histocompatibility complex and cell differentiation antigen expression patterns resemble those of human embryonic stem cell lines. Immunology 119:98–115PubMedCrossRefGoogle Scholar